Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Celgene will acquire Quanticel Pharmaceuticals, a privately held specialist in cancer drug discovery. The deal will give Celgene access to Quanticel’s platform for the single-cell genomic analysis of human cancer as well as Quanticel’s lead programs targeting specific epigenetic modifiers. The deal caps a 2011 collaboration between the companies, during which time Quanticel generated several drug candidates expected to begin clinical trials next year. Celgene will pay $100 million for Quanticel plus milestone payments of up to $385 million.
This article has been sent to the following recipient: